Sat, Apr 19, 2014, 11:04 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

iPath S&P 500 VIX ST Futures ETN Message Board

roc123 11 posts  |  Last Activity: Apr 3, 2014 4:19 PM Member since: Jan 20, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    The stock market is rigged

    by investorinvestor22 Apr 3, 2014 3:00 PM
    roc123 roc123 Apr 3, 2014 4:19 PM Flag

    Buy low, sell high :)

    Sentiment: Strong Buy

  • 6.65... eom

  • Reply to

    Sorry people.....

    by df2830 Mar 28, 2014 3:06 PM
    roc123 roc123 Mar 28, 2014 3:18 PM Flag

    Bought some.. between 21.75 ~ 21.00
    GLTA!

    Sentiment: Buy

  • roc123 roc123 Mar 27, 2014 11:13 PM Flag

    Bought some more yesterday ...
    GLTA :)

    Sentiment: Strong Buy

  • roc123 roc123 Mar 13, 2014 2:38 PM Flag

    Bought more......6.72 .

  • Reply to

    Taigen news update from Taiwan

    by roc123 Mar 12, 2014 11:08 PM
    roc123 roc123 Mar 12, 2014 11:31 PM Flag

    Why is Google translate Chinese-English so incredibly bad? LOL :)
    But good for ARNA!

    Sentiment: Strong Buy

  • Reply to

    Taigen news update from Taiwan

    by roc123 Mar 12, 2014 11:08 PM
    roc123 roc123 Mar 12, 2014 11:21 PM Flag

    F * 4157 New drug for marketing approval in Taiwan
    2014/03/13 10:00 Kui Heng Network reporter Zhang Xuhong Taipei

     

    Taiwan's biotech industry to write a new page ! Drug development quotient F * Taigen( 4157 ) , announced the Ministry of Health and Welfare Food and Drug Administration (TFDA) approval Taigen Biotechnology R & D of Nai Nuosha Star (Nemonoxacin, Tai Gitzo ®) oral dosage forms listed first in Taiwan TFDA examined by a new compound developed drug people .

    Tai Gitzo ® approved for listing in Taiwan , its manufacture by the United States ( 1795 ) OEM sales team established by the King too , due to the Southeast Asian region , except for Singapore and Malaysia , but also recognize Taiwan drug card , so King will also be application for listing matters Southeast Asian market as soon as possible .

    F * 4157Taigen said Tai Gitzo ® is a new non-fluorinated quinolone antibacterial drugs , there are two kinds of oral and injectable formulations . Taigen has completed clinical trials of oral formulations multinational multi- center clinical trial 1,282 subjects prove its safety and efficacy. Clinical trials proved Tai Gitzo ® can be effective against several drug-resistant bacteria , such as methicillin-resistant Staphylococcus aureus (MRSA), a quinolone resistant MRSA, as well as quinolone resistant Streptococcus pneumoniae and other stubborn bacteria. Because of that it has a broad spectrum, and drug design is not easy for bacteria to mutate , suitable as first-line therapy.

    F * 4157 Taigen made ​​in 2004 from Procter & Gamble (P & G) in the pharmaceutical sector Tai Gitzo ® authorized to take over from the clinical Phase Ia, actively developing patented clinical development plans and pharmaceutical manufacturing process of the follow-up of the indications , the extension of patent protection for life global patent owned up to 173 , patent protection up to 2029.
    http://tw.stock.yahoo.com/news_content/url/d/a/140313/2/4bbzl.html

    (Google translate)...

  • Good news from Taiwan( Google translate)
    F * Taigen subsidiary奈诺沙star review of inspection and registration permit oral dosage forms of drugs through
    2014/03/13 10:26 SysJust

     

    Stock Material Information Notice

    (4157) F * Taigen - on behalf of the major subsidiaries Taigen Biotechnology Co., Ltd. Notice Nainuo Sha Star oral dosage forms (Nemonoxacin ) , review by inspection and registration of new drugs (NDA) license

    1 Date of occurrence : 103/03/12
    2 Company Name: Taigen Biotechnology Co., Ltd.
    (3) the relationship with the company [ Enter Company or its subsidiaries ] : affiliates
    4 mutual shareholding ratio : 100%
    5 media Name: NA
    6 reported content : NA
    7 occur reason : the Ministry of Health and Welfare Food Drug Administration (TFDA) review by Taigen Biotechnology Co., Ltd. R & D奈诺沙Star (Nemonoxacin ) oral dosage form drug inspection and registration (NDA).
    8 Workaround: Manufacturing will continue to be listed on the pharmaceutical and ready to work.
    9 other matters that :
    (1 )奈诺沙star after listing in Taiwan listed tests to be performed ( ie, Phase IV trial).
    ( 2 ) Nainuo Sha star for a new generation of fluorine quinolones antibiotics can be effective against the growing proliferation of drug-resistant bacterial infections.
    Nai Nuosha star in the United States has completed the community-acquired pneumonia and diabetic foot infections are indications two Phase II clinical trials , and by the U.S. FDA granted " fast-track " (Fast Track) treatment , as belonging to fight drug-resistant bacteria " anti-infective products" (Qualified Infectious Disease Product, referred QIDP) qualifications, obtained permission to sell an additional five years alone , plus the New Chemical Entity NCE ( innovative compounds ) of five-year monopoly period to up to 10 years .
    奈诺沙star in Taiwan and China has completed Phase III clinical trials of oral formulations , and in March 2013 and April TFDA to Taiwan and China respectively

  • roc123 by roc123 Mar 3, 2014 10:03 AM Flag

    http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=4157:TT
    Last 62.20 TWD

    Change Today +1.10 / 1.80%

    Volume 5.5M

    Sentiment: Strong Buy

  • Reply to

    Yet another failed hedge fund panty raid.

    by apache118 Feb 26, 2014 3:05 PM
    roc123 roc123 Feb 26, 2014 3:09 PM Flag

    Shake and bake! lol

    Sentiment: Strong Buy

  • Reply to

    How Many Will Buy The Bear Raid?

    by biotechtrader13 Feb 26, 2014 2:09 PM
    roc123 roc123 Feb 26, 2014 2:39 PM Flag

    Bought some...6.81

    Sentiment: Strong Buy

VXX
41.71-0.64(-1.51%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Weibo Corporation
NasdaqGSThu, Apr 17, 2014 4:00 PM EDT